Clinical Trial

Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa

Study acronym: ADDICT
Recruiting
View on ClinicalTrials.gov →
Summary
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefiderocol or older agents such as aminoglycosides and colistin) in unselected patients with infection due to difficult-to-treat P. aeruginosa.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-12-13; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2025-04-16
Trial Details
NCT Number NCT06738771
Lead Sponsor Centre Hospitalier Régional d'Orléans
Conditions Pseudomonas Infections, Pseudomonas Aeruginosa, Prognosis, Drug Resistance, Multiple, Bacterial, Antibacterial Agents, Beta-lactam Antibiotics
Enrollment 600 participants
Start Date 2025-03-11
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-30